Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bryan Bell

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Biorxiv : the Preprint Server for Biology|January 30, 2023
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesDavid Knorr, Rom Leidner, Shawn Jensen, et al.
Plos One|November 15, 2017
STING expression and response to treatment with STING ligands in premalignant and malignant diseaseJason R Baird, Zipei Feng, Hong D Xiao, et al.
Plos One|February 16, 2018
Correction: STING expression and response to treatment with STING ligands in premalignant and malignant diseaseJason R Baird, Zipei Feng, Hong D Xiao, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinomaRom Leidner, Marka Crittenden, Kristina Young, et al.
JCI Insight|July 21, 2017
Multiparametric immune profiling in HPV- oral squamous cell cancerZipei Feng, Daniel Bethmann, Matthias Kappler, et al.
Oral Oncology|June 30, 2020
Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survivalChi T Viet, Eric J Dierks, Allen C Cheng, et al.
Nature Communications|February 17, 2021
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cellsRebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, et al.
Cancer Research|September 19, 2018
Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell CarcinomaJason R Baird, R Bryan Bell, Victoria Troesch, et al.
Head & Neck|August 25, 2025
Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaDavid M Cognetti, Joseph M Curry, Jennifer Johnson, et al.
Oral Oncology|October 10, 2022
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neckBrian J Park, Austin K Mattox, Daniel Clayburgh, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Biorxiv : the Preprint Server for Biology|January 30, 2023
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesDavid Knorr, Rom Leidner, Shawn Jensen, et al.
Plos One|November 15, 2017
STING expression and response to treatment with STING ligands in premalignant and malignant diseaseJason R Baird, Zipei Feng, Hong D Xiao, et al.
Plos One|February 16, 2018
Correction: STING expression and response to treatment with STING ligands in premalignant and malignant diseaseJason R Baird, Zipei Feng, Hong D Xiao, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinomaRom Leidner, Marka Crittenden, Kristina Young, et al.
JCI Insight|July 21, 2017
Multiparametric immune profiling in HPV- oral squamous cell cancerZipei Feng, Daniel Bethmann, Matthias Kappler, et al.
Oral Oncology|June 30, 2020
Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survivalChi T Viet, Eric J Dierks, Allen C Cheng, et al.
Nature Communications|February 17, 2021
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cellsRebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, et al.
Cancer Research|September 19, 2018
Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell CarcinomaJason R Baird, R Bryan Bell, Victoria Troesch, et al.
Head & Neck|August 25, 2025
Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaDavid M Cognetti, Joseph M Curry, Jennifer Johnson, et al.
Oral Oncology|October 10, 2022
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neckBrian J Park, Austin K Mattox, Daniel Clayburgh, et al.
Pageof 13